Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ TNXP opened at $0.19 on Thursday. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $26.08 million, a price-to-earnings ratio of 0.00 and a beta of 2.06. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $22.14. The business has a 50 day simple moving average of $0.15 and a 200-day simple moving average of $1.29.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. As a group, equities research analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.